Lyra Therapeutics, Inc. (LYRA)
0.19
0.00 (0.00%)
USD |
OTCM |
Oct 14, 16:00
Lyra Therapeutics Profit Margin (Quarterly) : -99.30K% for Dec. 31, 2025
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | -99.30K% |
| September 30, 2025 | -23.94K% |
| June 30, 2025 | -4.06K% |
| March 31, 2025 | -4.67K% |
| December 31, 2024 | -5.25K% |
| September 30, 2024 | -6.09K% |
| June 30, 2024 | -8.05K% |
| March 31, 2024 | -4.22K% |
| December 31, 2023 | -10.38K% |
| Date | Value |
|---|---|
| September 30, 2023 | -2.88K% |
| June 30, 2023 | -3.41K% |
| March 31, 2023 | -3.96K% |
| December 31, 2022 | -129.4K% |
| September 30, 2022 | -4.11K% |
| June 30, 2022 | -2.74K% |
| March 31, 2022 | -2.55K% |
| December 31, 2021 | -5.02K% |
| September 30, 2021 | -78.96K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Filana Therapeutics, Inc. | -- |
| CorMedix, Inc. | 25.50% |
| Eloxx Pharmaceuticals, Inc. | -- |
| Breakthrough Chemistry, Inc. | -43.31K% |
| BioStem Technologies, Inc. | -113.6% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -7.08K% |
| Return on Assets | -56.69% |
| Return on Invested Capital | -88.22% |
| Gross Profit Margin (Quarterly) | -1.33K% |
| Operating Margin (Quarterly) | -98.73K% |
| Return on Net Operating Assets | -147.8% |